Healthcare / BiotechnologyNasdaqGS
$1.88
+0.01 (+0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.7M · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.4%
↓Gross Margin
49.7%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+89.7%
FCF CAGR
—
FCF margin
-286.9%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.1M · net income $-73.6M · FCF $-46.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $16.1M | $16.1M | $13.9M | $15.2M | $14.7M | $6.6M | $656000.00 |
| Net Income | $-73.6M | $-73.6M | $-86.6M | $-86.3M | $-93.0M | $-71.2M | $-32.8M |
| EBITDA | $-71.9M | $-71.9M | $-93.9M | $-97.9M | $-93.3M | — | — |
| EPS | -1.28 | -1.28 | -1.39 | -1.35 | -1.49 | -1.17 | -2.48 |
| Gross Margin | 49.7% | 49.7% | 49.0% | 46.3% | 42.8% | 51.6% | 100.0% |
| Operating Margin | -483.9% | -483.9% | -717.7% | -681.5% | -662.1% | -1080.1% | -5129.4% |
| Net Margin | -456.6% | -456.6% | -620.9% | -568.3% | -633.1% | -1075.5% | -4996.2% |
| Balance Sheet | |||||||
| Debt/Equity | 0.09 | 0.09 | 0.08 | 0.07 | 0.07 | — | — |
| Current Ratio | 12.84 | 12.84 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-46.2M | $-46.2M | $-49.7M | $-66.4M | $-71.0M | $-53.3M | $-25.4M |
| Returns | |||||||
| ROE | -28.4% | -28.4% | -26.4% | -21.7% | -20.8% | -14.2% | -7.6% |
| Valuation | |||||||
| P/B | 0.42 | 0.42 | 0.47 | 0.29 | 0.64 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 15.6% | 15.6% | -8.1% | 3.4% | — | 908.7% | — |
| EPS Growth | 7.9% | 7.9% | -3.0% | 9.4% | — | 52.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.39 → -1.28
Residual
-2.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.